Loading organizations...
§ Private Profile · 1030 Massachusetts Ave Ste 140, Cambridge, Massachusetts, 02138, United States
Nested Therapeutics is a technology company.
Nested Therapeutics develops precision oncology medicines through a sophisticated drug discovery platform. It uncovers overlooked driver mutations in cancer, expanding targeted therapies to a broader patient population. Leveraging genomics, computational biophysics, machine learning, and chemical biology, the company identifies novel binding pockets to design highly specific small molecule therapeutics.
Nested Therapeutics was co-founded in 2021 by Arvin Dar, Ph.D., Kevan Shokat, Ph.D., and Klaus Hoeflich, Ph.D. Their insight addressed the critical gap where many cancer-driving mutations lack approved therapies and novel targeting mechanisms are overlooked. They established Nested to systematically identify and exploit these hidden opportunities.
Nested Therapeutics primarily serves cancer patients underserved by existing precision medicines. The company envisions expanding precision oncology by revealing new therapeutic possibilities. By identifying and targeting hidden driver mutations, Nested aims to deliver tailored treatments, reaching a broader patient population and transforming outcomes in complex cancers.
Nested Therapeutics has raised $125.0M across 2 funding rounds.
Nested Therapeutics has raised $125.0M in total across 2 funding rounds.
Nested Therapeutics has raised $125.0M across 2 funding rounds. Most recently, it raised $90.0M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 6, 2022 | $90M Series A | Goldman Sachs | Avidity Partners, Cowen Healthcare Investments, Foresite Capital, Section 32 | Announced |
| Dec 1, 2021 | $35M Seed | — | Casdin Capital, Versant Ventures | Announced |
Nested Therapeutics is a pre-clinical biotechnology company founded in 2021 and headquartered in Cambridge, MA, focused on advancing precision oncology by discovering hidden driver mutations in cancer to develop targeted small-molecule drugs.[1][2] The company builds a platform integrating genomics, structural biology, biophysics, computational biology, and machine learning to identify overlooked vulnerabilities, such as novel binding pockets or protein conformational changes, enabling non-degrading molecular glues like lead product NEST-1 and pipeline candidates NEST-2, NEST-3, and NEST-4 for oncology.[1][2] It serves cancer patients underserved by existing therapies, solving the problem of undetected mutations that limit precision medicine's reach, with strong growth momentum evidenced by $125M+ in funding (including $90M Series A in Oct 2022 from Versant Ventures, Foresite Capital, Avidity Partners, Cowen Healthcare Investments, and Section 32) and a team of 11-50 employees featuring pioneers in precision medicine.[1][2][4]
Nested Therapeutics emerged in 2021 from the vision of academic thought-leaders and biotech veterans aiming to push precision oncology beyond current limits by uncovering "driver mutations hiding in plain sight."[2] Key figures include CEO Darrin Miles, former Chief Medical Officer at ImmunoGen where she advanced ELAHERE™ for ovarian cancer; scientific co-founder Kevan Shokat (PhD from UC Berkeley), a serial entrepreneur behind companies like Revolution Medicines (RVMD) and Kura Oncology (KURA), whose lab pioneered covalent targeting of p53 mutants; and a multidisciplinary board with experts like Anna Berkenblit (former ImmunoGen CMO), Philip Komarnitsky (CMO), Tanja Weber (Chief Business Officer), and investors including Carlo Rizzuto, Josh Richardson, and Adriana Tajonar.[2][4] Early traction came swiftly with $35M seed funding pre-2022, followed by a $90M Series A in October 2022, fueling platform buildout and pipeline advancement in its first years.[1]
Nested Therapeutics rides the precision oncology wave, amplified by advances in AI-driven genomics and biophysics that reveal cryptic mutations, amid market forces like rising cancer incidence and demand for personalized therapies beyond blockbuster immunotherapies.[1][2] Timing is ideal post-2022 funding boom for molecular glues—a hot modality in 2025, as seen in related patents and market forecasts—aligning with biotech shifts toward computationally accelerated drug discovery to cut costs and speed pipelines.[1][3] It influences the ecosystem by expanding treatable mutations, potentially partnering with CROs or big pharma (e.g., via board networks), and contributing to Cambridge's biotech hub alongside peers like insitro and Eikon Therapeutics in mutation-targeted innovation.[2][4]
Nested Therapeutics is poised for clinical milestones, with NEST-1 likely advancing to IND filing soon given its pre-clinical momentum and expert leadership, while pipeline expansion (NEST-2/3/4) could tap molecular glue hype through 2030.[1][2] Trends like AI-biophysics integration and glue degraders will propel it, potentially drawing big pharma deals or IPO amid precision oncology's $100B+ market growth. Its influence may evolve from stealth innovator to ecosystem shaper, broadening patient access as in its mission—revealing limitless possibilities in hidden vulnerabilities.[2]
Nested Therapeutics has raised $125.0M in total across 2 funding rounds.
Nested Therapeutics's investors include Goldman Sachs, Avidity Partners, Cowen Healthcare Investments, Foresite Capital, Section 32, Casdin Capital, Versant Ventures.